# US 11,026,912 B2 · Azelaic acid esters in the treatment of insulin resistance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,026,912 B2
- Document ID: US11026912B2
- Status: Granted
- Kind: B2
- Application number: 16/267,338
- Filed: 2019-02-04
- Published: 2019-06-06
- Granted: 2021-06-08
- Earliest claimed: 2016-04-20
- Assignees: New Frontier Labs, LLC
- Applicants: New Frontier Labs, LLC
- Inventors: Robert T. Streeper; Elzbieta Izbicka
- Web page: https://patentgrep.com/patent/US11026912B2

## CPC

- A61K 31/225: Polycarboxylic acids
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/23: of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating insulin resistance includes administering to a subject a pharmaceutical composition comprising diethyl azelate. For example, a method of treating insulin resistance includes orally administering to a subject a pharmaceutical composition that includes diethyl azelate at a dosage range from about 0.1 mg/kg/day to about 10 mg/kg/day.

## Claims

### Claim 1

A method of treating Type 2 diabetes comprising administering to a subject a pharmaceutical composition comprising diethyl azelate at a dose in a range from 0.5 mg/kg/day to 2.5 mg/kg/day.

### Claim 2 (depends on 1)

The method of claim 1, wherein the administering step is performed enterically.

### Claim 3 (depends on 2)

The method of claim 2, where enteric administration is oral.

### Claim 4 (depends on 1)

The method of claim 1, wherein the administering step is performed parenterally.

### Claim 5 (depends on 4)

The method of claim 4, wherein the parenteral administration is performed intramuscularly, subcutaneously, intravenously, or combinations thereof.

### Claim 6 (depends on 1)

The method of claim 1, further comprising administering a second active ingredient.

### Claim 7 (depends on 6)

The method of claim 6, wherein the second active ingredient comprises one or more selected from the group consisting of a C1-C4 alkyl ester azelate different from diethyl azelate, a biguanide, a thiazolidinedione, a corticosteroid, insulin, a lipase inhibitor, a glucagon like peptide-1 (GLP-1) agonist, and combinations thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein the biguanide comprises metformin, buformin, phenformin, or combinations thereof.

### Claim 9 (depends on 7)

The method of claim 7, wherein the thiazolidinedione comprises pioglitazone, rosiglitazone, or combinations thereof.

### Claim 10 (depends on 7)

The method of claim 7, wherein the corticosteroid comprises prednisone.

### Claim 11 (depends on 7)

The method of claim 7, wherein the insulin is formulated as a rapid-acting formulation, an intermediate-acting formulation, a long-acting formulation, or combinations thereof.

### Claim 12 (depends on 7)

The method of claim 7, wherein the lipase inhibitor comprises orlistat.

### Claim 13 (depends on 7)

The method of claim 7, wherein the GLP-1 agonist comprises exenatide, liraglutide, and combinations thereof.